Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q1 2025 · 47 positions · Total reported value $2.19B · Top-10 concentration 70.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2025 13F filing, Frazier Life Sciences Management, L.P. disclosed 47 equity positions with a combined reported value of $2.19B. The filing implies a focused portfolio: its ten largest positions account for 70.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2025 were NAMS ($329.90M), MIRM ($306.12M), VRNA ($219.54M). By sector, the heaviest allocations are Health Care 83.1%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Other (+4.5pp) and away from Health Care (-4.4pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q1 2025 were MAZE ($45.46M), RNAM ($15.50M), DYN ($15.10M).

Of the 3 positions fully exited versus the prior quarter, the largest were EWTX ($33.94M), ANAB ($20.84M), PLRX ($14.76M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2025)

  • MAZE MAZE THERAPEUTICS INCORPORATED · $45.46M
  • RNAM AVIDITY BIOSCIENCES INC · $15.50M
  • DYN DYNE THERAPEUTICS INC · $15.10M
  • ZLAB Zai Lab Ltd · $12.65M

Fully Exited (vs previous quarter)

  • EWTX EDGEWISE THERAPEUTICS INC COM · prev qtr: $33.94M
  • ANAB ANAPTYSBIO INC · prev qtr: $20.84M
  • PLRX PLIANT THERAPEUTICS INC · prev qtr: $14.76M
  • DAWN DAY ONE BIOPHARMACEUTICALS I · prev qtr: $8.74M
  • ETNB 89BIO INC · prev qtr: $7.82M
  • ARVN ARVINAS INC · prev qtr: $5.47M
  • ELDN ELEDON PHARMACEUTICALS INC · prev qtr: $4.85M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 83.1%
Materials 0.2%
Other 16.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 16.12M $329.90M 15.08%
15.08%
Add
2 6.80M $306.12M 13.99%
13.99%
Add
3 3.46M $219.54M 10.03%
10.03%
Add
4 8.79M $137.40M 6.28%
6.28%
Hold
5 3.80M $131.38M 6.00%
6.00%
Hold
6 688.46K $124.13M 5.67%
5.67%
Reduce
7 1.75M $87.11M 3.98%
3.98%
Hold
8 1.40M $71.79M 3.28%
3.28%
Reduce
9 10.26M $64.53M 2.95%
2.95%
Reduce
10 10.11M $63.39M 2.90%
2.90%
Hold
11 4.89M $56.41M 2.58%
2.58%
Hold
12 4.13M $45.46M 2.08%
2.08%
New
13 5.99M $44.17M 2.02%
2.02%
Hold
14 678.76K $35.95M 1.64%
1.64%
Reduce
15 499.16K $35.66M 1.63%
1.63%
Reduce
16 997.46K $35.27M 1.61%
1.61%
Hold
17 11.46M $31.75M 1.45%
1.45%
Add
18 1.07M $31.35M 1.43%
1.43%
Hold
19 22.58M $30.93M 1.41%
1.41%
Add
20 658.72K $23.85M 1.09%
1.09%
Hold
21 133.33K $20.78M 0.95%
0.95%
Hold
22 539.40K $20.37M 0.93%
0.93%
Hold
23 601.13K $19.85M 0.91%
0.91%
Hold
24 690.01K $19.31M 0.88%
0.88%
Add
25 770.00K $18.86M 0.86%
0.86%
Hold
26 7.82M $17.59M 0.80%
0.80%
Add
27 373.10K $15.70M 0.72%
0.72%
Hold
28 525.00K $15.50M 0.71%
0.71%
New
29 10.62M $15.39M 0.70%
0.70%
Hold
30 1.44M $15.10M 0.69%
0.69%
New
31 350.00K $12.65M 0.58%
0.58%
New
32 301.17K $8.94M 0.41%
0.41%
Add
33 1.41M $7.87M 0.36%
0.36%
Reduce
34 470.34K $7.81M 0.36%
0.36%
Hold
35 1.95M $7.54M 0.34%
0.34%
Hold
36 1.08M $7.20M 0.33%
0.33%
Reduce
37 4.62M $7.17M 0.33%
0.33%
Hold
38 583.33K $5.98M 0.27%
0.27%
Hold
39 3.87M $5.65M 0.26%
0.26%
Add
40 1.25M $5.63M 0.26%
0.26%
Reduce
41 936.58K $5.61M 0.26%
0.26%
Hold
42 1.07M $4.67M 0.21%
0.21%
Hold
43 500.33K $4.50M 0.21%
0.21%
Hold
44 3.18M $4.03M 0.18%
0.18%
Hold
45 955.51K $3.32M 0.15%
0.15%
Hold
46 1.15M $3.24M 0.15%
0.15%
Hold
47 5.99M $1.55M 0.07%
0.07%
Hold

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2025-Q1?

In its 2025-Q1 13F filing, Frazier Life Sciences Management, L.P. reported 47 equity positions worth $2.19B in aggregate; its largest disclosed positions were NAMS ($329.90M), MIRM ($306.12M), VRNA ($219.54M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $2.19B of long equity holdings across 47 positions as of 2025-Q1. Top-10 holdings account for 70.2% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →